Registra't
CAMFiC

La teva cistella

25 de juny de 2021

Fonts d'informació per la vacunació COVID-19

Amb la col·laboració del grup de Vacunes de la CAMFiC hem fet aquest recull l'enllaços relacionats amb la vacunació de la COVID-19 que poden ser d'interès pels socis i sòcies de la CAMFiC.

Material

Principals fonts d'informació (enllaços amb actualitzacions periòdiques)
Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias
(25/06/2021) Suspend intellectual property rights for covid-19 vac Ed BMJ
(25/06/2021) Vaccination history for diphtheria and tetanus is associated covid severity
(25/06/2021) Investigation of SARS-CoV-2 infection in dogs and cats of humans diagnosed with COVID-19 in Rio de Janeiro, Brazil - PLOS ONE
(25/06/2021) Safety, tolerability, and immunogenicity CoronaVac (xina) Fase 1-2 in healthy 60a Lancet
(25/06/2021) Does tetanus vaccination contribute to reduced severity of the COVID-19 infection? - Elsevier
(22/06/2021) Estrategia de vacunación frente a COVID-19 en España
(18/06/2021) SARS-CoV-2 variants of concern and variants under investigation in England
(17/06/2021) Five priorities for universal COVID-19 vaccination - Lancet
(17/06/2021) Certificat COVID digital de la UE Gencat
(16/06/2021) Moving forward with an imperfect vaccine Lancet
(12/06/2021) A strategy for SARS-CoV-2 vaccination in Yemen
(12/06/2021) Immunogenicity and efficacy single dose Oxford Authors reply 2Lancet March 2021
(10/06/2021) Should we vaccinate children against SARS-CoV-2
(09/06/2021) Rapid antigen test screening tool SARS-CoV-2 asymptomatic Navarra E clinical merapid antigen test screening tool SARS-CoV-2 asymptomatic Navarra E clinical me
(08/06/2021) Certificat COVID digital de la UE - Salut
(08/06/2021) Epidemiology, not geopolitics, should guide COVID-19 donations Comment Lancet
(01/06/2021) EU Digital COVID Certificate
(01/06/2021) Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA
(01/06/2021) Certificado COVID Digital de la UE: Nace la pasarela de la UE con siete países un mes antes de la fecha prevista
(21/05/2021) Pfizer changes storage-summary may 2021
(18/05/2021) Appendix Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data - The Lancet
(14/05/2021) Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 years MMWR
(12/05/2021) Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK - The Lancet
(12/05/2021) Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data - The Lancet
(12/05/2021) Addressing COVID-19 vaccine hesitancy: is official communication the key? - The Lancet
(10/05/2021) Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
(07/05/2021) Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination MMWR (07/05/2021)
(06/05/2021) Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce
(06/05/2021) Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers - Amercan Medical Association
(04/05/2021) SARS-CoV-2 Infection after Vaccination in Health Care Workers in California Letter NEJM
(02/05/2021) Estratègia de vacunació enfront la COVID a Catalunya - Proposta d’allargar interval entre dosis en situació de lliurament insuficient de vacunes - Grup de Seguiment de la Vacunació enfront la COVID-19 a Catalunya
(30/04/2021) SARS-CoV-2 Variant Classifications and Definitions CDC
(27/04/2021) Fighting misinformation in the time of COVID-19, WHO
(25/04/2021) Análisis de la efectividad y el impacto de la vacunación frente a COVID-19 en residentes de centros de mayores en España
(25/04/2021) Recomendaciones para el diagnóstico y tratamiento de eventos trombóticos tras la vacunación frente a COVID-19
(24/04/2021) Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
(22/04/2021) SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands
(21/04/2021) Impact of COVID-19 on COPD and asthma
(21/04/2021) Impacte en residents grans CAT Carmen Cabezas Lancet
(21/04/2021) Recomendaciones ante adenopatías axilares - vacunación COVID_Madrid
(20/04/2021) Recomendaciones SEDIM tras vacunación Adenopatias
(20/04/2021) Estrategia de vacunación frente a COVID19 en España
(20/04/2021) Vacuna frente a la COVID-19 de Janssen: conclusiones de la evaluación del riesgo de trombosis junto con trombocitopenia
(19/04/2021) Primer ensayo clínico que combina diferentes-vacunas Covid en ESP
(17/04/2021) Clarifying the evidence on SARS-CoV-2 antigen rapid tests Comment Lancet
(17/04/2021) Thromboembolism and oxford vac Side effect or coincidence Lancet
(12/04/2021) Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women JAMA
(11/04/2021) Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination - The new england journal of medicine
(07/04/2021) Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 - The new england journal of medicine
(07/04/2021) Vaxzevria® (vacuna frente a la COVID-19 de AstraZeneca): actualización sobre el riesgo de trombosis - Agencia Española de Medicamentos y Productos Sanitarios
(06/04/2021) Documento NO HACER en vacunas contra la COVID-19 - semFYC
(02/04/2021) Vaccine effectiveness frontline worker MMWR
(02/04/2021) Effectiveness mRNA vac MMWR
(02/04/2021) Vaccine certificates: does the end justify the means? - The Lancet
(01/04/2020) COVID-19 vaccine response in pregnant and lactating women Jobste april 2021
(31/03/2020) Prioritising COVID-19 vac in changing social epidemiological landscapes - The Lancet
(31/03/2021) Posicionamiento de la Sociedad Española de Reumatología (SER) sobre vacunación frente a la COVID-19
(31/03/2021) The interplay between COVID-19 restrictions and vaccination - The Lancet
(31/03/2021) Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination - The New England Journal of medicine
(30/03/2021) Vac Oxford Eficacia enfront variant UK- The Lancet
(30/03/2021) Manifiesto SERAM Vacunación SARS-CoV-2 con vacuna de ASTRAZENECA para profesionales
(30/03/2021) Recomendaciones realtivas al seguimiento de sospecha de trombosis y trombocitopenias tras la vacunación frente a COVID-19 - FACME
(30/03/2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B117): an exploratory analysis of a randomised controlled trial - The Lancet
(30/03/2021) Estrategia de vacunación frente a COVID-19 en España - Consejo Interterritorial Sistema Nacional de Salud
(30/03/2021) A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination - Research Square
(27/03/2021) Protection against reinfection Denmark Lancet
(26/03/2021) CDC Interim Recommendations for Fully Vaccinated People An Important First Step - American Medical Association
(25/03/2021) Recomendaciones relativas al seguimiento de sospechas de reacciones adversas tras la vacunación frente a COVID-19 - FACME
(24/03/2021) Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines) - EMA
(24/03/2021) Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2? - Elsevier
(24/03/2021) Comunicación dirigida a profesionales sanitarios COVID-19 Vaccine Astrazeneca: Riesgo de trombocitopenia y trastornos de la coagulación - EMA y Astrazeneca
(24/03/2021) Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening - Oxford University Press for the Infectious Diseases Society of America
(18/03/2021) Vacuna frente a la COVID-19 de AstraZeneca: conclusiones de la evaluación del riesgo de tromboembolismo - Agencia Española del Medicamentos y Productos Sanitarios
(11/03/2021) EMA fitxa tècnica Covid 19 vaccine Janssen
(11/03/2021) EMA summary positive opinion about covid-19-vaccine-Janssen
(10/03/2021) CDC Interim Recommendations for Fully Vaccinated People An important First Step - American Medical Association
(06/03/2021) Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster - The Lancet
(06/03/2021) Correcting COVID-19 vaccine misinformation Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members - Elsevier
(04/03/2021) Immunogenicity and efficacy single dose and timing booster Oxford Lancet March 2021
(02/03/2021) Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England - medrxiv
(27/02/2021) Fact sheet for recipients and caregivers emergency use authon (EUA) of the Janssen COVID-19 vaccine
(26/02/2021) Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination
(26/02/2021) FDA Briefing Document Janssen Ad26COV2S Vaccine for the Prevention of COVID-19
(26/02/2021) Estrategia de vacunación frente a COVID19 en España - Grupo de Trabajo Técnico de Vacunación COVID-19
(25/02/2021) Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals - The Lancet
(25/02/2021) Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine - The Lancet
(25/02/2021) Novetats i estratègia de vacunació contra la COVID-19 a l'atenció primària - Salut Cat
(23/02/2021) Neutralization of SARS-CoV-2 lineage B117 pseudovirus by BNT162b2 vaccine - elicited human sera - Science
(22/02/2021) Impact of the influenza vaccine on COVID-19 infection rates and severity - Elsevier
(19/02/2021) Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
(19/02/2021) Nota informativa: Programa de Targeta Groga i Vacunes de la COVID-19 Què cal notificar? - Dep Salut
(18/02/2021) Could mixing COVID Vaccine Bolster Immune response?- Springer Nature
(17/02/2021) What does 95% COVID-19 vaccine efficacy really mean? - The Lancet
(16/02/2021) Instruccions per a la vacunació del grup 4: persones amb grans dependències, incloent-hi els seus cuidadors - Departament de Salut
(12/02/2021) COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020 - US Department of Health and Human Services/Centers for Disease Control and Prevention
(12/02/2021) Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment - The Lancet
(11/02/2021) The impact of immuno-aging on SARS-CoV-2 vaccine
(08/02/2021) Actualització de la vacuna Astra Zeneca pel Departament de Salut
(05/02/2021) Determinants acceptance COVID-19 vac, a challenge in a fast-moving situation Comment Lancet Feb 2021
(04/02/2021) Covid-19: Israel sees new infections plummet following vaccinations BMJ
(02/02/2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia - Lancet
(02/02/2021) Sputnik V COVID-19 vaccine candidate appears safe and effective - The Lancet
(01/02/2021) Robust spike antibody responses and increased reactogenicity in seropositive individuals after a 2 single dose of SARS-CoV-2 mRNA vaccine BMJ
(29/01/2021) EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU
(28/01/2021) SARS-CoV-2 testing for public health use: core principles and considerations for defined use settings - The Lancet
(23/01/2021) Practice update COVID 19 disease spotlight
(21/01/2021) Nota informativa sobre reacciones a la primera dosis de la vacuna en individuos que ya han pasado la enfermedad - SEI
(20/01/2021) Webinar sobre vacunació COVID-19 als professionals sanitaris: on som? Consell de col·legis de metges de Catalunya
(19/01/2021) Cardiovascular Deaths During the COVID-19 Pandemic in the United States
(15/01/2021) Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020
(15/01/2021) Recomanacions de vacunació contra la COVID-19 (Informació per a professionals de la salut 6a actualització)
(15/01/2021 ) Les vacunes pel SARS-CoV-2: Professionals de la Salut Carmen Cabezas, SGPS
(14/01/2021) Posiconamiento de la Sociedad Española de inmunologia (SEI) sobre vacunación en pacientes que ya han superado la COVID-19
(13/01/2021) BMJ open Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain
(12/01/2021) Criterios para descartar infección aguda por SARS-CoV-2 tras la vacunación semFYC
(12/01/2021) Aging and covid jan 2021 review
(08/01/2020) WHO Episode #20 - COVID-19 - Variants & Vaccines
(06/01/2021) Genetic Variants of SARS-CoV-2-What Do They Mean jama_2021
(05/01/2021) Informació per a professionals de la salut Gencat
(05/01/2021) Informació per la Ciutadania Gencat
(02/01/2021)Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
(01/01/2021) Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease
(31/12/2020) Interim Considerations: Preparing for the Potential Management of Anaphylaxis After COVID-19 Vaccination (CDC)
(31/12/2020) Maintaining Safety with SARS-CoV-2 Vaccines Mariana C Castells, MD, PhD, and Elizabeth J Phillips, MD NEJM
(31/12/2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (Pfizer)
(31/12/2020) WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access
Vacunación COVID-19, Ministerio de Sanidad
COVID y vacunas: informe técnico del grupo Infecciosas del PAPPS-semFYC (24/12/2020)
(23/12/2020) Información sobre las vacunas contra el COVID-19 (CdC)
(22/12/2020) Carmen Cabezas, subdirectora general de Promoció de la Salut, afirma que la vacuna és voluntària, però assegura que és totalment segura i efectiva, i "ens ajudarà a sortir d'aquesta situació i evitar més morts":
(21/12/2020) L’Agència Europea del Medicament (EMA) recomana la primera vacuna COVID-19 per a la seva autorització a la Unió Europea (EMA Europa)
(21/12/2020) L’Agencia Europea del Medicament (EMA) recomana la primera vacuna COVID-19 per a la seva autorització a la Unió Europea (AEMPS)
(21/12/2020) La AEMPS lanza una campaña sobre las garantías de las vacunas frente a la COVID-19
(21/12/2020) WHO Getting vaccines, medicines and tests ready for emergency use
(18/12/2020) Estrategia de vacunación frente a COVID-19 en España
(18/12/2020) An emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019
(17/12/2020) Update on assessment of marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine
(10/12/2020) Les vacunes per fer front el coronavirus (SARS-Cov-2) Carmen Cabezas, Subdirectora General de Promoció de la Salut:
(04/12/2021) The challenges of distributing COVID-19 vaccinations
(02/12/2020) Estratègia de vacunación frente a COVID-19 en España
(01/12/2020) EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine
(25/11/2020) WHO Episode #5 - Vaccines
(21/11/2020) Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
Hoja informativa para proveedores de atención médica que administran vacunas Autorización de uso de emergencia (EUA) de la vacuna contra la covid-19 de Moderna

Cercador

Cercar